Bachem (OTCMKTS:BCHMF – Get Free Report) is projected to issue its resultson Thursday, July 30th. Analysts expect Bachem to post earnings of $0.5030 per share and revenue of $397.8930 million for the quarter.
Bachem Stock Performance
Shares of Bachem stock opened at $87.34 on Thursday. Bachem has a 1 year low of $60.51 and a 1 year high of $94.62. The company has a 50 day simple moving average of $88.51 and a two-hundred day simple moving average of $83.19.
Bachem Company Profile
Bachem Holding AG is a Switzerland‐based specialty biochemical company focused on the development, manufacturing and commercialization of peptides and oligonucleotides. Serving pharmaceutical and biotechnology clients as well as academic research institutions, the company offers a broad spectrum of products ranging from custom peptide synthesis for research applications to clinical and commercial‐grade active pharmaceutical ingredients (APIs). Bachem’s expertise extends to process development, scale‐up and GMP‐compliant production, supporting projects in therapeutic areas such as oncology, metabolic disorders and infectious diseases.
Founded in 1971 and headquartered in Bubendorf, Switzerland, Bachem has grown through strategic investments in production capacity and the acquisition of complementary peptide and oligonucleotide technologies.
Recommended Stories
- Five stocks we like better than Bachem
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Bachem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bachem and related companies with MarketBeat.com's FREE daily email newsletter.
